Oral MS drug Gilenya has yet to show ‘full potential'
Posted: Wed Apr 27, 2011 11:50 pm
Novartis's multiple sclerosis pill Gilenya, which faces a threat from a rival product under development by Biogen Idec Inc, has yet to show its full potential, the Swiss drugmaker’s head of development said.
Gilenya, approved by U.S. regulators last year as the first pill against relapsing forms of multiple sclerosis, may also work in patients with a more severe form of the disease called primary progressive, Novartis’s Trevor Mundel said yesterday in a telephone interview. “We haven’t seen the full potential with Gilenya,” according to Mundel.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309